Comparison

Elicit alternatives for systematic reviews (2026): an honest comparison

By Antonio Brundo · 10 June 2026 · Updated 10 June 2026

Direct answer: Elicit is a genuinely good systematic review tool — mature screening workflow, published accuracy claims, PRISMA support — and if your evidence lives entirely in the academic paper corpus and you run reviews continuously, its subscription may be exactly right. The honest reasons to look at alternatives are corpus breadth (Elicit searches one aggregated paper index; some questions need trials registries, regulations, or patents), output depth (screening tables and reports vs a complete IMRAD manuscript), citation verification architecture, and pricing model ($49–169/month subscriptions vs paying per deliverable). This comparison is written by AutoSearch — one of the alternatives — so we name our bias and stick to checkable criteria.

First, what Elicit does well

Any "alternatives" article that opens by trashing the incumbent should not be trusted, so let's be accurate. Elicit offers one of the most mature AI-assisted systematic review workflows on the market: search across an aggregated index of 138M+ academic papers, structured data extraction into columns, a dedicated screening workflow (up to 5,000 papers on the Pro plan, with much larger screening capacity at enterprise tier), and PRISMA-oriented reporting added in 2025. Unusually for this market, Elicit publishes accuracy claims for its extraction features and is open about residual error rates. If your workflow is "screen a large set of academic papers against criteria and extract variables," Elicit is a credible default.

Pricing at the time of writing: a free Basic tier (limited reports per month), Pro at $49/month, Scale at $169/month, and custom enterprise plans — i.e., a recurring subscription scaled by report volume and screening capacity.

The criteria that actually separate these tools

Most "Elicit alternatives" listicles are written by the alternatives themselves and compare adjectives. These five criteria are checkable in an afternoon with a trial account:

• Corpus — which sources can the tool actually query? One aggregated paper index, or also trial registries, regulatory databases, preprint servers, patents?
• Citation verification — does the tool verify that references resolve (and against what), or does it trust the model's output?
• Methodology disclosure — can you export a search log, screening decisions, and a PRISMA flow generated from real counts?
• Output format — a screening table, a narrative report, or a complete structured manuscript you can submit or file?
• Pricing model — subscription (pay monthly regardless of usage) vs per-deliverable (pay when you produce something).

AutoSearch (yes, this is our product)

AutoSearch approaches the same problem from the document-out rather than the screening-in direction: you define a research question, the system runs a protocol-first search across 12 source families — PubMed, ClinicalTrials.gov, Crossref, OpenAlex, Semantic Scholar, arXiv, DOAJ, EUR-Lex, DataCite, and patent and corporate sources — screens and logs every record, and produces a complete IMRAD manuscript with LaTeX/PDF export, a PRISMA flow diagram generated from the actual run counts, and an audit trail.

The architectural differentiator is citation handling: a reference can only enter the output if its DOI resolves on Crossref and passes a semantic relevance check — fabricated citations are excluded by construction, not detected afterwards (details in how we verify DOIs via Crossref, and why this matters in our analysis of fabricated citations in AI tools). Pricing is per-deliverable credits rather than a subscription, which favours teams that run reviews periodically (e.g., annual regulatory updates) rather than daily. There is also an MCP server, so agents and IDEs can drive runs programmatically.

Where Elicit is stronger, honestly: very large-volume screening with human-in-the-loop review of every record, published per-feature accuracy benchmarks, and a more mature collaborative UI for teams doing extraction work all day.

Side-by-side

Other alternatives worth knowing

Consensus

Built around answering questions with aggregated findings from academic papers ("what does the research say about X"), with a meter summarising agreement across studies. Excellent for rapid evidence checks; not designed to produce a documented systematic review with a search protocol and exclusion log.

Scite

Unique citation-context data: it shows whether citing papers support or contrast a claim. Best used as a complement to any review workflow — appraisal support rather than search-and-write automation.

Undermind

An agentic deep-search tool that iteratively refines queries over the scholarly literature. Strong at discovery on hard questions; the output is a research briefing, not a PRISMA-documented review.

SciSpace

A broad toolbox (chat with PDFs, literature maps, writing aids) with a large user base. Breadth is the appeal; users evaluating it for systematic reviews should test how far the credit allowances stretch for their workload before committing, a recurring theme in public user reviews.

Paperguide / PapersFlow

Newer entrants combining reference management with AI review features. Worth a trial if you want lightweight all-in-one tooling; methodology disclosure is thinner than the dedicated SR tools above.

What this comparison deliberately leaves out

We have not scored extraction accuracy head-to-head, because vendor-run benchmarks of competitors are exactly the kind of marketing this article is trying not to be. Where a vendor publishes its own accuracy numbers (Elicit does), we say so and treat it as a point in their favour. For everything else, the criteria above are designed so you can verify them yourself with trial accounts rather than taking anyone's word — including ours.

Which tool for which user

• Academic running large screening projects continuously — Elicit's screening workflow and subscription model fit; add Scite for appraisal.
• Regulatory affairs / medtech — you need trial registries and regulatory sources in the corpus, an audit trail, and a re-runnable strategy for PMCF cadence; this is AutoSearch's home turf (see the MDR/IVDR use case).
• Occasional reviewer (a few reviews per year) — per-deliverable pricing beats a standing subscription; compare total cost for your actual volume.
• Quick evidence checks — Consensus, or any of the chat-first tools; you don't need SR machinery (see AutoSearch vs ChatGPT for literature review for where chat tools stop).

FAQ

Is Elicit's single-index corpus actually a problem?

For most pure-academic questions, no — the aggregated index covers the bulk of published papers. It becomes a problem when your evidence includes registered trials without publications, regulations, standards, or patents, or when a reviewer (or notified body) asks why only one information source was searched.

Can these tools replace a human systematic reviewer?

No tool on this page honestly claims that. The defensible division of labour: software executes search, screening logistics, logging, and drafting; humans own eligibility judgement calls, risk-of-bias appraisal, and conclusions. Our methodology page spells out exactly which steps AutoSearch automates and which it deliberately leaves to you.

Test it on your own question

The cheapest way to compare is empirical: run the same research question through Elicit's free tier and an AutoSearch run, and compare the source coverage, the citation verification, and the deliverable. See the full tool comparison or start a free run.